Hutchmed touts first-in-class cancer platform with GSK deal
SingTao · 1 SOURCESabout 1 hour ago6 MIN
Summary
Hutchmed, the drug developer under CK Hutchison, said it has been developing a first-in-class precision oncology platform called ATTC, or antibody-targeted therapy conjugates, aimed at improving on conventional antibody-drug conjugates. The company says the approach uses small-molecule payloads instead of highly toxic chemotherapy payloads, with the goal of killing cancer cells more precisely while reducing harm to healthy cells and lowering side effects for patients. Chief Financial Officer Zheng Zefeng (鄭澤鋒) said the platform is intended to complement, rather than replace, existing cancer treatments, and may be particularly suitable for first-line use and combination therapy in earlier-stage treatment settings. He added that HMPL-A830, an ATTC candidate that is about to enter clinical development, has already been licensed to GSK under a global collaboration and could ultimately have peak sales worth tens of billions of US dollars, potentially above US$10 billion
Key Points
- Hutchmed said many approved or clinical-stage targeted cancer drugs use ADC technology, where antibodies deliver a payload into tumour cells like a guided bomb
- According to Zheng, conventional ADC payloads often rely on highly toxic chemotherapy agents, which can leave resistant cancer cells behind and also damage healthy cells
- Hutchmed said its ATTC platform replaces that payload with small-molecule drugs, combining antibody activity with a second mechanism for more precise dual-action targeting
- The company has five ATTC programmes in development, including two already in clinical trials and HMPL-A830, which is expected to start this year’s second half
- HMPL-A830 is covered by an exclusive global development and licensing agreement with GSK, initially focused on colorectal, pancreatic and lung cancers, with deal value around US$1.3 billion
Why It Matters
For Hong Kong investors, the story points to how a locally listed biotech group is trying to move beyond licensing income toward potentially large global oncology products. For patients, the company’s pitch is that earlier-line, more precise targeted treatment could reduce side effects while fitting alongside existing therapies rather than displacing them outright